Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Head & Neck 1Gynecologic 1Endocrine 1Breast 1

Conditions

Sarcoma 189Osteosarcoma 72Sarcoma, Ewing 49Rhabdomyosarcoma 44Melanoma 40Neuroblastoma 35Gastrointestinal Stromal Tumors 34Neoplasms 32Colorectal Neoplasms 29Glioblastoma 28Bone Neoplasms 27Neoplasm Metastasis 26Ovarian Neoplasms 25Breast Neoplasms 25Wilms Tumor 22Gliosarcoma 22Glioma 22Rhabdoid Tumor 21Lymphoma, Non-Hodgkin 21Sarcoma, Kaposi 20Liposarcoma 20Carcinoma, Non-Small-Cell Lung 20Pancreatic Neoplasms 18Neurofibrosarcoma 18Medulloblastoma 18Hepatoblastoma 18Carcinoma, Renal Cell 18Lymphoma 17Thyroid Neoplasms 16Desmoid Tumors 16

Interventions

fludarabine 1aldesleukin 1Nivolumab 1Ipilimumab 1Cyclophosphamide 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Giant Cell Tumor of Bone × Sarcoma × 90 days × Clear all
NCT03449108 2026-05-22

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
30 enrolled
BreastEndocrineGynecologicHead & NeckSarcoma

Bone Neoplasms, Ovarian Neoplasms, Sarcoma, Osteosarcoma, Giant Cell Tumor of Bone, Histiocytoma, Malignant Fibrous, Triple Negative Breast Neoplasms, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡